Abstract
Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500nm and a spherical shape.
Keywords: Radiopharmaceuticals, Oncology, Nuclear Medicine, Hypoxia, Predictive.
Current Radiopharmaceuticals
Title:Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Volume: 5 Issue: 4
Author(s): Marta de Souza Albernaz, Beatriz Ferreira de Carvalho Patricio, Gilberto Weissmuller, Franceline Reynaud, Tom CH Adamsen and Ralph Santos-Oliveira
Affiliation:
Keywords: Radiopharmaceuticals, Oncology, Nuclear Medicine, Hypoxia, Predictive.
Abstract: Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500nm and a spherical shape.
Export Options
About this article
Cite this article as:
de Souza Albernaz Marta, Ferreira de Carvalho Patricio Beatriz, Weissmuller Gilberto, Reynaud Franceline, CH Adamsen Tom and Santos-Oliveira Ralph, Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?, Current Radiopharmaceuticals 2012; 5 (4) . https://dx.doi.org/10.2174/1874471011205040336
DOI https://dx.doi.org/10.2174/1874471011205040336 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo
Current Organic Chemistry Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Glioblastoma Multiforme and its Cell Interruption
Current Cancer Therapy Reviews Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides
Current Pharmaceutical Biotechnology Chemopreventive Properties of Peptide Lunasin: A Review
Protein & Peptide Letters BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry Nutrition and NSCLC; Should We Administer Food Supplements?
Current Pharmaceutical Design ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry The Development of PDGF Receptor Inhibitors for the Treatment of Glioma: A Review
Letters in Drug Design & Discovery MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Current Drug Targets